These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 31037128)

  • 1. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
    Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
    Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
    Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
    Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helvolic acid attenuates osteoclast formation and function via suppressing RANKL-induced NFATc1 activation.
    Chen K; Yuan Y; Wang Z; Song D; Zhao J; Cao Z; Chen J; Guo Q; Chen L; Tickner J; Xu J
    J Cell Physiol; 2019 May; 234(5):6477-6488. PubMed ID: 30341897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.
    Lin X; Yuan G; Yang B; Xie C; Zhou Z; Liu Y; Liu Z; Wu Z; Akimoto Y; Li N; Xu R; Song F
    Phytomedicine; 2024 Jul; 129():155559. PubMed ID: 38579642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation.
    Xu Y; Song D; Lin X; Peng H; Su Y; Liang J; Hai N; Zhao J; Liu Q
    Free Radic Biol Med; 2023 Feb; 196():121-132. PubMed ID: 36649902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
    Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
    Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
    [No Abstract]   [Full Text] [Related]  

  • 9. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
    Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
    Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
    Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
    Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways.
    Xiao L; Zhong M; Huang Y; Zhu J; Tang W; Li D; Shi J; Lu A; Yang H; Geng D; Li H; Wang Z
    Aging (Albany NY); 2020 Nov; 12(21):21706-21729. PubMed ID: 33176281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling.
    Xiao Y; Li K; Wang Z; Fu F; Shao S; Song F; Zhao J; Chen W; Liu Q; Xu J
    J Cell Physiol; 2019 Aug; 234(8):13959-13968. PubMed ID: 30633330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of a prominent dihydroxyflavanone pinocembrin for osteolytic bone disease:
    Hong G; Li S; Zheng G; Zheng X; Zhan Q; Zhou L; Wei Q; He W; Chen Z
    J Orthop Translat; 2024 Mar; 45():197-210. PubMed ID: 38685969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active fraction of Polyrhachis vicina (Rogers) inhibits osteoclastogenesis by targeting Trim38 mediated proteasomal degradation of TRAF6.
    Feng X; Wei G; Su Y; Xian Y; Liu Z; Gao Y; Liang J; Lian H; Xu J; Zhao J; Liu Q; Song F
    Phytomedicine; 2024 Sep; 132():155890. PubMed ID: 39033726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice.
    Zhao D; Wang Q; Zhao Y; Zhang H; Sha N; Tang D; Liu S; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B
    Menopause; 2018 Dec; 25(12):1459-1469. PubMed ID: 29944638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
    Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
    Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathways.
    Qin Y; Song D; Liao S; Chen J; Xu M; Su Y; Lian H; Peng H; Wei L; Chen K; Xu J; Zhao J; Liu Q
    Biomed Pharmacother; 2023 Apr; 160():114347. PubMed ID: 36746095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-
    Wong P; Lv Z; Li J; Wei Q; Xu L; Fang B; Luo Y; He M
    Oxid Med Cell Longev; 2022; 2022():5982014. PubMed ID: 36388169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.